We report on our experience with preimplantation genetic diagnosis (PGD) for single gene disorders (SGDs), from 1999 to 2004, describing strategies and overall clinical outcome of 250 cycles in 174 couples for 23 different genetic conditions. METHODS: PGD cycles included 15 for autosomal dominant, 148 for autosomal recessive and 19 for X-linked SGDs. In addition, 68 cycles of PGD for SGDs were performed in combination with HLA matching. The strategy in each case used an initial multiplex PCR, followed by minisequencing to identify the mutation(s) combined with multiplex PCR for closely linked informative markers to increase accuracy. Linkage analysis, using intragenic and/or extragenic polymorphic microsatellite markers, was performed in cases where the disease-causing mutation(s) was unknown or undetectable. RESULTS: In 250 PGD cycles, a total of 1961 cleavage stage embryos were biopsied. PCR was successful in 3409 out of 3149 (92.4%) biopsied blastomeres and a diagnosis was possible in 1849 (94.3%) embryos. Four hundred and twenty-seven embryos were transferred in 211 cycles, resulting in 71 pregnancies (33.6% per embryo transfer), including 15 biochemical pregnancies, six spontaneous miscarriages, two ectopic pregnancies, which were terminated, and nine pregnancies which are still ongoing. The remaining pregnancies were confirmed to be unaffected and went to term without complications, resulting in the birth of 35 healthy babies. CONCLUSIONS: Minisequencing for mutation detection combined with multiplex fluorescence PCR for linkage analysis is an efficient, accurate and widely applicable strategy for PGD of SGDs. Our experience provides a further demonstration that PGD is an effective clinical tool and a useful option for many couples with a high risk of transmitting a genetic disease.
Introduction
Couples at high risk of transmitting an inherited disease to their offspring have the option of undergoing prenatal diagnosis to allow the detection of the genetic disorder in the fetus. However, if the analysis reveals a genetically affected fetus, the only options available to couples are to have a child with a genetic disease or to terminate the affected pregnancy. This is a difficult and often traumatic decision, especially in advanced pregnancies. Many couples may also experience repeated pregnancy terminations in attempts to conceive a healthy child and might feel unable to accept further affected pregnancies.
PGD has been introduced as an alternative to prenatal diagnosis, to increase the options available for couples who have a known genetically transmittable disease, providing reassurance and a reduced anxiety associated with reproduction. The intended goal of PGD is to diagnose a specific genetic disease in embryos, obtained through IVF, before a clinical pregnancy has been established, by selecting and transferring to the mother only embryos found to be unaffected after mutation analysis. Consequently, PGD may spare the couple decisions regarding possible pregnancy termination, giving them the opportunity to start a pregnancy with the knowledge that their child will be unaffected by the specific genetic disorder (Braude et al., 2002; Sermon et al., 2004) .
Following its first application in 1990 (Handyside et al., 1990) , PGD has become an important complement to the presently available approaches for prevention of genetic disorders and an established clinical option in reproductive medicine. Since then, the numbers of centres performing PGD has risen steadily, along with the number of diseases that can be tested (International Working Group on Preimplantation Genetics, 2001; ESHRE PGD Consortium Steering Committee, 2002; Sermon et al., 2005) , and new applications and methodologies are introduced regularly. The range of genetic defects which can be diagnosed has expanded dramatically and now includes numerical and structural chromosomal abnormalities (Munnè et al., 2000; Wilton, 2002) and most of the common single gene disorders (SGDs) (Vandervorst et al., 2000; Pickering et al., 2003) . The scope of PGD has also been extended to screening for chromosomal aneuploidies in IVF patients at increased risk, including advanced maternal age and repeated miscarriage Munnè et al., 2002; Rubio et al., 2003) . More recently, HLA typing, with or without SGD diagnosis, has been introduced with the aim of recovering compatible stem cells from cord blood at birth for transplantation to an existing sick child (Verlinsky et al., 2001; Fiorentino et al., 2004 Fiorentino et al., , 2005 Van de Velde et al., 2004; Rechitsky et al., 2004) .
Although a growing number of clinics are offering PGD, mainly for aneuploidy screening, the overall experience of using PGD for SGDs remains restricted to only a few centres worldwide. To date it is estimated that PGD has been applied in >50 different SGDs in >1000 cycles, resulting in the birth of >300 unaffected children (International Working Group on Preimplantation Genetics, 2001; ESHRE PGD Consortium Steering Committee, 2002; Sermon et al., 2005) .
Here we present our experience of using PGD for SGDs from 1999 to 2004, describing strategies and overall clinical outcome of 250 PGD cycles performed for 23 different genetic conditions.
Materials and methods

Case referrals and patient counselling
A total of 174 couples were included in the PGD programme over a 6 year period (Table I) . Maternal age ranged from 21 to 44, with a mean age of 31.8 ± 4.3 years. Referrals were received from IVF centres, geneticists and gynaecologists. Patients were counselled by a clinical geneticist, who first assessed the feasibility of carrying out the diagnosis of the genetic disease at single cell level. Genetic counselling consisted of reviewing the couple's genetic history and their reason(s) for requesting PGD, followed by an explanation of the PGD process for the specific genetic disorder and a discussion on the possible diagnostic options. A calculation of the genetic risk, the possible genetic outcomes, the success rates and the risk of misdiagnosis were also discussed. Finally the patients were referred to an assisted reproduction clinic to arrange the clinical aspects of the treatment.
During the initial consultation, a blood sample from both partners and affected children (when available) was taken as required for preclinical PGD work-up. Time needed to develop the test at single cell level averaged 1.5 months.
Written informed consent was obtained from all the couples, in which the possible risk of misdiagnosis was specified and confirmatory prenatal diagnosis for any ensuing pregnancy was always recommended.
Pre-clinical work-up
Determination or confirmation of the genetic status of the couples was performed as previously described . PCR amplification of each region of interest was performed using the outer oligonucleotide primers listed in Table II or reported elsewhere (Fiorentino et al., , 2004 (Fiorentino et al., , 2005 Iacobelli et al., 2003) . Short tandem repeat (STR) markers (Table III) , closely linked to the disease-causing genes, were included to avoid a possible misdiagnosis resulting from allele dropout (ADO). STR markers were also included to determine the copy number of chromosomes 21, 18 and 13, in patients of advanced maternal age (≥37 years of age).
The reliability of each protocol was evaluated before clinical application on single lymphocytes collected from both parents, as previously described .
IVF and embryo biopsy procedure
The majority of the patients were stimulated according to standard protocols (Fiorentino et al., , 2004 Iacobelli et al., 2003) . Other patients followed the specific protocols used by the referring clinics. In all cases, ICSI was used to reduce the risk of contamination with spermatozoan DNA. Selection of embryos for biopsy and the biopsy procedure were performed as described elsewhere (Fiorentino et al., , 2004 Iacobelli et al., 2003) , using either the acid Tyrode's protocol or a non-contact infrared laser for zona drilling. According to the biopsy policy, one blastomere was removed from embryos with <7 cells and two blastomeres from embryos with ≥7 cells. After biopsy, each blastomere was washed several time through drops of Ca 2+ /Mg 2+ -free EB-10 medium (Vitrolife, Gothenburg) and transferred into a sterile 0.2 ml PCR tube containing 5 μl of alkaline lysis buffer (200 mmol/l KOH, 50 mmol/l dithiothreitol). Blank controls from the wash drops for each blastomere were also included. Before proceeding to cell lysis, each tube was overlaid with one drop of PCR-grade mineral oil (SigmaAldrich, Milan, Italy). The samples were then placed on a rack, refrigerated by using wet ice, holding a 4°C temperature, and transported from the clinics to the PGD laboratory in Rome for genetic analysis. The transportation took 3 h, on average, and genetic analysis usually started within 6 h after the end of the biopsy procedure.
Cell lysis and multiplex PCR DNA analysis of blastomeres was carried out on the same day as biopsy. Before proceeding to multiplex PCR, cells were lysed by incubation at 65°C for 10 min. The alkaline lysis buffer was then neutralized by the addition of 5 μl of neutralization buffer (900 mmol/l Tris-HCl, 300 mmol/l KCl, 200 mmol/l HCl).
The technical details of the PCR protocols used for cystic fibrosis, β-thalassaemia, sickle cell anaemia, haemophilia A, retinoblastoma, spinal muscular atrophy, Charcot-Marie-Tooth type X and HLA matching have been described elsewhere (Fiorentino et al., , 2004 (Fiorentino et al., , 2005 Iacobelli et al., 2003) . For the other diseases, a nested multiplex PCR assay was used. The first round of PCR contained the external primers for the amplification of the gene regions involved by mutations, STR markers linked to these regions for ADO detection and those used for detection of aneuploidies in patients with advanced maternal age. The first round of multiplex PCR was followed by a separate second round PCR for each locus. PCR conditions used were reported earlier (Fiorentino et al., , 2004 (Fiorentino et al., , 2005 . The annealing temperature depended on the specific primers used (Table II) .
Mutation analysis in single cells
The strategy used for mutation analysis and mutations investigated are described in Table I . A fluorescent PCR protocol, involving multiplex amplification of one exon located in the deleted region and one nondeleted exon, was used for Duchenne muscular dystrophy. Mutation analysis for primary dystonia and myotonic dystrophy was performed by fluorescent amplification of the gene region surrounding the Cod.302 del GAG mutation in exon 5 of the DYT1 gene and the CTG repeat region in the 3′-untranslated region of the DMPK gene, respectively. Linkage analysis was the strategy preferred for neurofibromatosis type 1 (NF1), using fluorescent primers listed in Table II , and for congenital adrenal hyperplasia (CAH), using the STR markers MIB, MIC-A, 62, TNFa, LH-1 and DRA-CA described elsewhere (Fiorentino Table I 
Neurofibromatosis type 1
NF1
Intron 26
Intron 38 , 2004) . For the other genetic disorders, mutation analysis was performed using the minisequencing method, as previously reported . Fluorescent fragments were analysed by 20 min of capillary electrophoresis on an automatic DNA sequencer ABI Prism 3100™ (Applied Biosystems).
Embryo transfer
Embryo transfer was carried out on either day 4 or day 5. The number of the embryos transferred varied according to the number of unaffected embryos available after diagnosis, the age of the patient and the morphology of the embryos. When the quality was comparable, non-carrier embryos were transferred in preference to heterozygous embryos.
Confirmation of PGD results
As specified in the informed consent, following successful embryo transfer, affected or morphologically incompetent embryos were collected in individual tubes and reanalysed to confirm the PGD results. Supernumerary unaffected embryos were cryopreserved if cleavage continued.
In cases in which pregnancies were achieved, patients were advised to undergo conventional prenatal diagnosis to confirm the genetic status of the fetus.
Results
Over a 6 year period, 174 couples underwent 250 PGD cycles for 23 different indications (Table I ). The mean maternal age was 31.8 ± 4.3 years, ranging from 21 to 44. Of the 174 couples included in the treatment, 122 underwent only one PGD cycle, 33 had two, 16 had three, two had four and one couple had six attempts. In total, 248 were stimulated cycles and two were frozen embryo replacement cycles.
The single gene defects investigated included autosomal dominant (15 cycles; eight couples), autosomal recessive (148 cycles; 107 couples) and X-linked disorders (19 cycles; 10 couples). A total of 68 cycles, for 49 couples, were also performed for SGDs combined with HLA matching.
Myotonic dystrophy was the most frequent autosomal dominant disease tested (n = 6; 40.0%). β-Thalassaemia was the most frequent autosomal recessive disorder (n = 105; 70.9%), followed by cystic fibrosis (n = 25; 16.9%), spinal muscular atrophy (n = 6; 4.1%) and sickle cell anaemia (n = 5; 3.4%). Duchenne muscular dystrophy (n = 5; 26.3%) and haemophilia A (n = 5; 26.3%) were the most frequent X-linked disorders investigated.
A total of 1961 embryos (mean number 7.8 ± 3.7 per cycle) were biopsied and two cells were removed in 1448 (73.8%) for analysis (Table IV) . PCR amplification was successful in 3149 out of 3409 blastomeres (92.4%). Amplification failed for all the markers/loci tested in 260 blastomeres. The efficiency of amplification for the individual genetic conditions ranged from 80.0 to 100%, with an overall amplification rate of 92.4%. The ADO rates varied between the different loci/markers investigated, ranging from 0 to 12.9%, with an average ADO rate of 7.5% (data not shown).
Overall, 1849 (94.3%) embryos were successfully genotyped in the 250 clinical cycles. In 1231 embryos, the final diagnosis was obtained from the concordant results of two cells, whereas for 618 embryos the diagnosis was based on one blastomere only. No diagnosis was obtained for 112 embryos.
Embryos suitable for transfer where identified in 211 of the 250 cycles (84.4%). In nine PGD cycles, embryo transfer was cancelled because unaffected embryos were not found. Similarly, in 30 cycles of PGD for SGDs combined with HLA matching, transfer was cancelled because no unaffected HLAmatched embryos were found.
Following transfer of 427 embryos (mean 2.0 ± 0.8, range 1-3), 71 women had positive HCG levels (33.6% pregnancy rate per embryo transfer), 56 of which were confirmed with fetal sacs and heart beat (26.5% implantation rate per embryo transferred). Six pregnancies spontaneously miscarried within the first trimester and two ectopic pregnancies were terminated. Prenatal diagnosis was performed in the remaining pregnancies using either chorion villus sampling or amniocentesis. All pregnancies were confirmed to be unaffected; nine pregnancies are still ongoing, whereas the others went to term without complications, resulting in the birth of 35 healthy babies.
Two hundred and fifty-two untransferred embryos were reanalysed to confirm the diagnosis and this was successful in 231 (91.7%) embryos. The genotypes were concordant for all embryos (data not shown).
The largest group of PGD cycles (105 for 75 couples) was performed for β-thalassaemia. Of 871 embryos analysed, 829 (95.2%) yielded a successful diagnosis. There were 37 genotype combinations, involving the diagnosis of 20 different β-thalassaemia mutations. Genotype analysis involved detection of a single mutation in 48 cycles, and two mutations in 57 cycles. Two hundred and twelve unaffected embryos were transferred in 105 cycles, resulting in 35 pregnancies (33.3% pregnancy rate per embryo transfer) and the birth of 15 healthy children.
Cystic fibrosis was the second most common indication for PGD in our experience. A total of 25 cycles were carried out for this disease, involving analysis of 147 embryos, of which 145 (98.6%) were successfully diagnosed. Eleven genotype combinations were tested, involving the diagnosis of 11 different cystic fibrosis mutations, the most common of which was DeltaF 508. Genotype analysis involved detection of one mutation in nine cycles, and two mutations in 16 cycles. Sixty unaffected embryos were transferred back to the patient in 24 cycles, resulting in seven clinical pregnancies (29.2%) and the birth of six unaffected children.
PGD for SGDs was also used in combination with HLA typing in 68 cycles performed for 49 couples. A total of 618 embryos were tested involving analysis of 1054 blastomeres, in 974 (92.4%) of which a successful amplification was obtained. Overall, 58 unaffected HLA-matched embryos were transferred to the patients in 38 of the 64 cycles performed (mean 1.5 ± 0.8 ). Twelve pregnancies were achieved (31.6% per transfer), four of which were only biochemical, one resulted in early abortion, and one ectopic pregnancy was terminated. From one twin and three singleton pregnancies, five healthy children were born, which were confirmed to be HLA identical to their affected sibling by HLA testing blood samples.
Discussion
In the past two decades, knowledge of the molecular basis of genetic diseases, together with the development of new DNA technologies, has enabled early and exact diagnosis of an increasing number of congenital disorders and the identification of patients at increased risk of having affected offspring. In this context, PGD has become an established approach for early diagnosis of genetic disorders, providing the opportunity, for couples who have a known genetically transmittable disease, to start a pregnancy with the knowledge that their child will be unaffected by the specific disorder tested. Although it is more than a decade since the first PGD for SGD was performed (Handyside et al., 1992) , the complexity of the approach has so far limited its clinical application. PGD is a multidisciplinary procedure that requires combined expertise in reproductive medicine and molecular genetics . Thus, even if the numbers of centres performing PGD is increasing steadily, only a few centres worldwide are offering PGD for SGDs as a clinical service.
From 1999 we have been offering PGD for SGDs as a diagnostic service, and our experience over 6 years highlights many positive aspects and some potential limitations.
The first practical obstacle we encountered was to address the growing number of requests for PGD for different indications, some of which were rare diseases. In 15 cases performed for 14 different genetic conditions, the disease-causing mutations, carried by the patients, were also unknown. As a consequence, design and optimization of protocols for mutation screening of causative genes were necessary to determine the genetic status of the couples. Furthermore, for most of these genes, mutation detection was complicated by the presence of a large number of exons.
Another complication, associated with performing PGD for different genetic diseases, was represented by the time needed to optimize the specific protocols for each case. To validate a diagnostic single cell PCR protocol, before clinical application, extensive pre-clinical trials on single lymphocytes are necessary, in order to evaluate single cell amplification efficiencies and ADO rates for all the primers to be used in the procedure. Consequently, some of the couples included in the PGD programme had to wait several months before beginning the cycle. We partially addressed this limitation by using a PGD strategy characterized by a nested-PCR protocol producing amplicons analysable by the minisequencing technique , avoiding the use of mutation-based strategies that require optimization of specific PCR protocols for each mutation to be analysed. The minisequencing approach has proven to be extremely flexible and appropriate for the analysis of a wide spectrum of mutations and compound genotypes (Figure 1 ). Its usefulness is evident particularly for the diagnosis of genetic diseases characterized by a large number of different mutations concentrated in a few exons (i.e. β-thalassaemia) or with a cluster of frequent mutations on a short distance (i.e. cystic fibrosis). Although each PGD case can involve the presence of different mutations and genotype combinations, the use of a panel of PCR primers tested pre-clinically enables a substantial shortening of the preliminary phase for each couple.
Minisequencing was applied in 234 PGD cycles for 17 different indications, involving the analysis of 49 different mutations and 65 genotype combinations (Table I) . The strategy has proven to be extremely efficient, as it provides a high rate of interpretable results in blastomeres in which amplification is successful (98.7%). The accuracy of the genotyping method was established previously during the validation of the procedure The y-axis represents the relative fluorescence units (RFU) of the detected fragments; the x-axis represents time and is displayed by data points. Colour is assigned to individual ddNTPs as follows: green/A, black/C, blue/G, red/T. Mutation IVSI-110 G-A is shown on the left of the minisequencing window; the blue peak represents the normal allele (wild-type base G), the green peak (mutant base A) the mutated allele. Mutation IVSI-6 T/C is shown on the right; the red peak is the normal allele (wild-type base T) and the black peak (mutant base C) is the mutated allele. Embryo 1 (upper panel/left) is a carrier for the IVSI-6 T/C mutation; embryo 3 (upper panel/right) is normal; embryo 2 (lower panel/left) is compound heterozygote for the two mutations. Embryo 4 (lower panel/right) is also affected, although the minisequencing result shows a heterozygosity for mutation IVSI-110 G-A. In fact, linked STR markers highlight an ADO of the affected allele (black peak, mutant base C). and has also been monitored by later reanalysis of non-transferred embryos and by prenatal diagnosis of the ensuing pregnancies, confirming in all cases the clinical diagnosis obtained during PGD cycles.
To increase the level of diagnostic accuracy, hence reducing the chances of misdiagnosis, wherever possible two cells from each embryo were biopsied. Diagnosis was assigned only when both cells yielded concordant results or, as in cases where only one cell result was available (one cell biopsy or total amplification failure in one cell), when haplotype profiles, obtained from linked STR markers, and mutation analysis profiles were concordant. Despite the biopsy of two cells in most of the embryos investigated, pregnancy and implantation rates were apparently not significantly affected. In fact, pregnancy was initiated in 33.6% of the cycles, with embryo transfer and the average clinical pregnancy rate was 26.5%. These results are comparable with those reported for single gene disorders by other groups using a one-cell biopsy policy (Pickering et al., 2003; Traeger-Synodinos et al., 2003) and with the ESHRE PGD Consortium data (ESHRE PGD Consortium Steering Committee, 2002; Sermon et al., 2005) . On the other hand, our experience with the biopsy and analysis of two blastomeres demonstrates that this is an effective strategy especially when amplification failure of one of the two cells of the embryo occurs, increasing the number of successfully diagnosed embryos available for transfer.
Including a panel of polymorphic STR markers in the diagnostic assay, closely linked to the gene regions containing the disease-causing mutations, has also increased the robustness of the diagnostic procedure. In fact, determination of the specific STR haplotype associated with the mutation acts both as a diagnostic tool for indirect mutation analysis, providing an additional confirmation of the results obtained with the direct genotyping procedure, and as a control of misdiagnosis due to undetected ADO (Rechitsky et al., 1999) (Figures 1 and 2) . The multiplex STR marker system also provides an additional control for contamination with exogenous DNA, as other alleles, differing in size from those of the parents, would be detected (Piyamongkol et al., 2001) . The experience of this series of PGD cycles strongly suggests that PGD protocols for SGDs are not appropriate for clinical practice without including a set of linked STR markers; consequently, this strategy is currently followed for all our PCR protocols.
For myotonic dystrophy, characterized by the presence of a dynamic mutation involving the expansion of a trinucleotide repeat sequence, a multiplex fluorescent PCR protocol was used. Since the large expanded alleles are refractive to PCR amplification, a general approach, allowing detection of only healthy alleles, was applied. The PGD strategy involved amplification of the DNA fragment around the repeated region and STR markers linked to this region for ADO detection (Sermon et al., 1998; Dean et al., 2001) .
A multiplex fluorescent PCR protocol, including simultaneous testing of the DYT1 gene mutation and a set of linked polymorphic markers, was also used for early-onset primary dystonia, an autosomal dominant disorder caused, in most of the cases, by a 3bp deletion (codon 302) in the DYT1 gene. Mutation analysis was performed simply by sizing PCR fragments, detecting the affected alleles because of the 3bp difference from the normal allele (Figure 2 ). Because this mutation is responsible for >70% of primary dystonia cases, the PGD strategy used can be applied for most patients without the need for extensive pre-clinical preparatory work.
The single cell PCR protocol used for Duchenne muscular dystrophy, a disease characterized by large deletions of one or more exon(s) of the dystrophin gene in ∼60% of Duchenne muscular dystrophy patients, involved multiplex amplification of one exon located in the deleted region, one non-deleted exon as an internal PCR control and a panel of informative polymorphic intragenic STR markers for ADO detection and discrimination of carrier embryos. Fluorescent PCR was preferred over conventional PCR (Ray et al., 2001; Girardet et al., 2003) because the sensitivity is several orders of magnitude higher, increasing accuracy and reliability (Findlay et al., 1995 (Findlay et al., , 1998 . Furthermore, fluorescencebased protocols are highly amenable to multiplexing, which has great potential when applied to simultaneous detection of mutation sites and linked STR markers (Figure 3 ). PGD has also been used in our Centre for several indications beyond its original purpose, although their application is still controversial because they raise ethical issues. In 68 cycles, PGD was used not only to test embryos for a monogenic disorder, but also to select embryos for a non-disease trait, such as specific HLA genotypes, related to immune compatibility with an existing affected child in need of a haematopoietic stem cell transplant. A preimplantation HLA-matching assay, involving haplotyping of the HLA region by analysing different polymorphic STR markers located along the HLA complex, was optimized and clinically applied in 49 couples, with the purpose of selecting embryos HLA matched with the existing affected offspring. Using this approach, the HLA region was indirectly typed by segregation analysis of the STR alleles and comparison with the affected sibling (Fiorentino et al. 2004 (Fiorentino et al. , 2005 . The assay is highly accurate in the selection of HLAmatched embryos for transfer. Overall, eight clinical pregnancies have been established, resulting in the birth of five healthy HLA-matched children, representing one of the most extensive series of clinical cases and complementing other similar experiences on preimplantation HLA matching (Rechitsky et al., 2004; Van de Velde et al., 2004) .
In five cycles, PGD was performed for detection of inherited cancer predisposition. At-risk couples, who requested PGD for retinoblastoma and NF1, wished to avoid the birth of children with the inherited predisposition to malignancy, without having to face the option of possible pregnancy termination. In the NF1 patient, the predisposing germline mutation was unknown. Due to the difficulty associated with mutation screening of the NF1 gene because of the presence of a large number of exons, linkage analysis was performed to determine the presence of the haplotype associated with mutation, thereby avoiding the need for direct mutation detection. After obtaining a family pedigree by testing family members, four polymorphic STR markers (Table II) located within the NF1 gene were used to determine which alleles were inherited along with the undetected mutation.
Linkage analysis was also the strategy used in the PGD cycle for CAH, performed in a consanguineous couple with an affected child, even though the disease-causing mutation is known. In this case, during the pre-clinical work-up, following mutation analysis of the CYP21A2 gene, both partners were found to be homozygotes for the nucleotide 656 A-C→G mutation, without showing any clinical signs of the disease. Non-amplification of the normal allele at nucleotide 656 is a known phenomenon described in asymptomatic carriers (Day et al., 1996; Van de Velde et al., 1999) . These putative nucleotide 656 G/G individuals are incorrectly typed due to dropout of the normal allele during PCR amplification. In order to overcome the ambiguity at nucleotide 656, instead of direct detection of the mutation, a PGD strategy involving linkage analysis through multiplex fluorescent PCR of six STR markers flanking the CYP21A2 gene was developed (Figure 4) .
Because of the consanguinity of the couple, the affected child was showing a homozygous microsatellites profile (Figure 4) . In order to exclude a multiple ADO occurrence leading to misdiagnosis of a healthy heterozygous embryo, which would appear affected and would not be transferred, a large number of STR markers was used. Although no pregnancy was achieved for this case, later reanalysis of untransferred embryos confirmed the results, indicating that this method could represent a reliable and flexible approach applicable to PGD of a wide spectrum of different genotype combinations causing 21-hydroxylase deficiency.
The described PCR protocols undertaken for this series of genetic conditions were efficient and accurate at single cell level. Results from both clinical cases and follow-up confirmation provided a high overall amplification rate (92.4%), with ADO rates ranging from 0 to 12.9%, depending on the PCR assay. These results are within the expected range for single cell PCR (Thornhill et al., 2005) and allowed an accurate genotyping of 94.3% of the embryos analysed.
Working as a separate PGD centre, in collaboration with different IVF centres, the embryo biopsy procedure was performed far from the laboratory where the diagnostic analysis was carried out. As a consequence, in most cases, blastomeres were transported over a long distance in lysis buffer in PCR tubes, refrigerated at 4°C. However, as demonstrated by the high overall amplification rate obtained, transportation does not seem to affect amplification efficiency and final diagnosis, determining only a delay of ∼6 h in starting the PGD procedure, although we cannot exclude that the amplification failure observed with some of the blastomeres could be a consequence of cell loss, for example during transportation.
In conclusion, the clinical outcome of these cycles provides a further demonstration that PGD is an effective clinical tool for assisted reproduction and genetic screening, confirming the experience of other groups (Vandervorst et al., 2000; Harper et al., 2002; Pickering et al., 2003; Traeger-Synodinos et al., 2003; Verlinsky et al., 2004; de Boer et al., 2004) . From the patients' perspective, PGD is an important alternative to standard prenatal diagnosis. Low pregnancy and birth rates, and the high cost of the procedure, however, make it unlikely that PGD will supersede completely the more conventional methods of prenatal testing. PGD remains a complex combination of different technologies, that involves reproductive medicine as well as clinical and molecular genetics and requires the close collaboration of a team of specialists. Rapid advances in molecular genetics are likely to stimulate further use of PGD and to encourage a substantial increase in the range of genetic conditions for which PGD is offered. The accuracy of procedures will be improved and its clinical application will be simplified. In the future, PGD will play an increasing role as a specialized clinical procedure, becoming a useful option for many more couples with a high risk of transmitting a genetic disease, to prevent the birth of children affected by monogenic defects.
